Promising phase 2B trial results of Lanifibranor in NASH
During this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (p...
									
									
									
									
									
									
									
									
									
									